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ABSTRACT
Objectives The ALIGN study (NCT01061723)
evaluated the efﬁcacy and safety of sarilumab, the ﬁrst
fully human monoclonal antibody against interleukin-6
receptor-α (IL-6Rα), in patients with ankylosing
spondylitis (AS).
Methods Patients with active AS despite conventional
treatment were randomised to placebo, or one of ﬁve
subcutaneous dose regimens of sarilumab (100, 150 or
200 mg every other week, or 100 or 150 mg every
week), for 12 weeks. The primary efﬁcacy end point was
the percentage of patients achieving the Axial
SpondyloArthritis international Society (ASAS) 20
response criteria at week 12. Secondary endpoints
included ASAS40 response, ASAS partial remission,
AS Disease Activity Score, high-sensitivity C-reactive
protein (hs-CRP) value, and safety.
Results Baseline demographic and disease
characteristics of the 301 patients enrolled were similar
across treatment groups. At week 12, there was no
statistically signiﬁcant difference in ASAS20 response rate
between placebo (ASAS20 = 24.0%) and any sarilumab
dose group. A signiﬁcantly greater reduction in hs-CRP
value was achieved with the higher sarilumab doses
versus placebo. No other statistically signiﬁcant
differences were evident for secondary efﬁcacy
endpoints.
The most common treatment-emergent adverse events
reported for sarilumab included infections (non-serious),
neutropenia, and increase in alanine aminotransferase.
No cases of tuberculosis, opportunistic, or fungal
infections, or bowel perforations were reported. Seven
patients experienced a treatment-emergent serious
adverse event (all in sarilumab treatment groups).
No deaths occurred.
Conclusions The ALIGN study shows that IL-6Rα
blockade with sarilumab was not an effective treatment
for AS. Sarilumab was generally well tolerated with a
manageable safety proﬁle.
INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inﬂammatory
disease that typically develops in the third decade of
life,1–3 affecting men about twice as frequently as
women.3 A close relationship exists between the
prevalence of the HLA-B27 gene and the develop-
ment of AS, with 80–95% of patients with AS being
HLA-B27 positive.4 Traditional therapies, such as
non-steroidal anti-inﬂammatory drugs (NSAIDs),
have limited efﬁcacy in many patients. Although bio-
logic agents have signiﬁcantly improved outcomes,
30–40% of patients experience substantial disease
activity despite anti-tumour necrosis factor (TNF)-α
therapy.5–7 For some patients, the initial response to
anti-TNF-α agents diminishes over time and they are
switched to another anti-TNF agent.8 However, if
TNF-blockade fails to control AS disease activity, no
other treatment options are currently available.
Because high levels of TNF-α and interleukin (IL)-6
have been found in biopsy specimens from sacroiliac
joints of patients with AS, these cytokines were
thought to at least partially mediate the inﬂammation
in AS.9–12 Circulating levels of IL-6 also correlate
with spinal inﬂammation,13 and the clinical and
radiological efﬁcacy of TNF-blockade in AS is asso-
ciated with signiﬁcant reduction of IL-6 and
C-reactive protein (CRP) levels.14 Thus, blockade of
IL-6 is an appealing potential therapeutic option.
Tocilizumab (TCZ) is a humanised monoclonal
antibody against IL-6 receptor-α (IL-6Rα), and is
approved for the treatment of rheumatoid arthritis
(RA).15 When the current study was designed and
initiated, case reports suggested beneﬁt with TCZ
in AS patients who had been refractory to two or
more anti-TNF agents.16–19 After the study had
been completed, negative results of a placebo-
controlled trial of tocilizumab in patients with
active AS were reported.20 No anti-IL-6 agent is
currently approved for the treatment of AS.
Sarilumab, the ﬁrst fully human monoclonal anti-
body directed against IL-6Rα, is currently in devel-
opment for RA. The phase II ALIGN study reported
here evaluated the efﬁcacy and safety of ﬁve subcuta-
neously (SC) administered sarilumab dose regimens
versus placebo in anti-TNF-naive patients with active
AS despite treatment with NSAIDs.
METHODS
Study design
ALIGN was a randomised, multicentre, double-
blind, parallel-group, placebo-controlled study con-
ducted in 68 study centres in Europe, Canada and
the USA (NCT01061723). The study duration was
22 weeks, including 4 weeks of screening, 12 weeks
of treatment and 6 weeks of post-treatment
follow-up. Patients were randomised with balanced
allocation to receive either SC placebo or sarilumab
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(100, 150 or 200 mg every other week (q2w), or 100 or
150 mg every week (qw), with q2w dosing alternating with
placebo) for 12 weeks. Patients were stratiﬁed according to
levels of high-sensitivity (hs)-CRP (≤1.5 mg/dL or >1.5 mg/dL)
at screening and region (Western countries vs non-Western coun-
tries). Patients who completed the 12-week treatment period
were offered enrolment in a long-term extension study,
NCT01118728. Patients who chose not to enrol in the exten-
sion study had a post-treatment safety follow-up visit 6 weeks
after the end-of-treatment visit. Further details regarding sched-
uling of clinic visits are provided in online supplemental
materials.
This study was performed in compliance with Good Clinical
Practice. The appropriate institutional review boards/ethics com-
mittees approved the study, and written informed consent was
obtained from each patient before study participation.
Patients
Consecutively enrolled patients were randomised using a central
randomisation scheme generated by an Interactive Voice
Response System. All data were collected during scheduled
clinic and home visits. Patients included in the study were men
and women between the ages of 18 and 75 years, had had
active AS for at least 3 months, and Bath AS Disease Activity
Index (BASDAI)21 and total back pain score ≥4 at screening and
baseline, without complete fusion of the spine, and did not
respond adequately to, or were intolerant of, ≥2 NSAIDs (each
taken for ≥2 weeks). Patients treated with oral prednisone or
equivalent corticosteroids (≤10 mg/day) must have been taking a
stable dose for ≥2 weeks prior to baseline. Patients treated with
the disease-modifying anti-rheumatic drugs hydroxychloroquine
(≤400 mg/day), sulfasalazine (≤3 g/day) or methotrexate (MTX)
(≤25 mg/week) must have been on a stable dose ≥12 weeks
prior to baseline.
Patients were excluded from the study if they had a past history
of non-response to any anti-TNF-α agent or non-response to any
other biological treatment for AS, had received treatment with a
disease modifying anti-rheumatic drug (DMARD) (except those
allowed in the inclusion criteria) or any biological agent within
3 months prior to screening, had received oral prednisone or
equivalent corticosteroids >10 mg/day within 6 weeks prior to
screening, intramuscular or intra-articular corticosteroids within
4 weeks of screening, or had previously been treated with cyclo-
sporine or azathioprine.
Study objectives and efﬁcacy endpoints
The primary study objectives were to evaluate sarilumab efﬁcacy
during the 12-week treatment period according to the Axial
SpondyloArthritis international Society (ASAS)2022 outcome
measure in patients with AS, and to deﬁne the best dose/dosage
regimen for further development.
The primary efﬁcacy endpoint was the percentage of patients
who achieved the ASAS20 response criteria at week 12. This was
deﬁned as an improvement of at least 20% and an absolute
improvement of at least one unit relative to baseline on a 0–10
numerical rating scale (NRS) in at least three of the following
four ASAS improvement criteria (ASAC-IC) domains: physical
function (Bath AS Function Index (BASFI)),23 total back pain,
patient global assessment and inﬂammation (mean of intensity
and duration of morning stiffness components from the
BASDAI); and no worsening ≥20% and ≥1 unit relative to base-
line on a scale of 0–10 NRS in the remaining fourth domain.
Secondary efﬁcacy end points at week 12 included the per-
centage of patients who achieved: ASAS40 response (as for
ASAS20, with improvement ≥40% and absolute improvement
≥2 units), ASAS partial remission (value of ≤2 units on a 0–10
NRS in each of the four ASAS-IC domains), ASAS5/6 response
(composite score of six domains ie, ASAS-IC, spinal mobility
Figure 1 Patient disposition. SC, subcutaneous; q2w, every 2 weeks; qw, every week.
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and hs-CRP, response being 20% improvement in ﬁve domains
without deterioration in the sixth), and change from baseline in:
ASAS individual components, MRI score of the spine (AS spine
MRI-active scoring system, ASspiMRI-a), AS Disease Activity
Score (ASDAS) score, BASDAI score, Bath AS Metrology Index
(BASMI, 11-point scale), hs-CRP value and chest expansion.
The incidences of swollen and tender joints were not captured,
and the impact of sarilumab on peripheral disease was not assessed.
Sample size calculation
On the basis of previous trials with biologics in AS, it was
assumed that the response rates would be 25% in the placebo
group and 60% in at least one of the active treatment groups.
With 50 patients per group, the study had ∼80% power to detect
a difference of 35 percentage points between any dose of sarilu-
mab and placebo using a two-sided test with α=0.01 due to the
application of Hommel’s procedure to adjust for multiplicity.
Statistical analyses
Primary efﬁcacy analysis
The primary efﬁcacy end point, ASAS20 response at week 12,
was assessed to demonstrate that at least one sarilumab dose
differed from placebo. Comparisons made between each sarilu-
mab dose group and the placebo group were adjusted for multi-
plicity using Hommel’s procedure. ASAS20 response at week 12
was analysed using the two-sided Cochran–Mantel–Haenszel
test stratiﬁed by screening hs-CRP and region. Pairwise compari-
sons of response rates and 95% CIs for ORs between each sari-
lumab dose and placebo were derived by testing each active
dose group versus placebo separately. The Mantel–Haenszel esti-
mate of the OR and the corresponding 95% CIs were derived
the same way.
A last-observation-carried-forward procedure was used to
impute any missing ASAS20 components for patients who missed
at least one ASAS component at week 12 for any reason. Patients
who discontinued study treatment due to lack of efﬁcacy before
week 12 were considered as non-responders. Treatment-by-sub-
group interactions were also analysed for ASAS20 response.
Secondary efﬁcacy analyses
Binary secondary efﬁcacy end points, for example, ASAS40
response, ASAS partial remission and ASAS5/6 response at week
12 were analysed as deﬁned above for the primary efﬁcacy end
point.
Table 1 Patient demographics and baseline characteristics—randomised population
Sarilumab
Placebo
(n=50)
100 mg q2w
(n=49)
150 mg q2w
(n=50)
100 mg qw
(n=52)
200 mg q2w
(n=50)
150 mg qw
(n=50)
All
(n=301)
Demographics
Age, years, mean (SD) 40.3 (11.7) 42.4 (10.8) 43.0 (11.3) 40.4 (11.5) 37.2 (10.4) 41.1 (11.1) 40.7 (11.2)
Male, n (%) 38 (76.0) 30 (61.2) 34 (68.0) 37 (71.2) 40 (80.0) 39 (78.0) 218 (72.4)
Caucasian/white, n (%) 49 (98.0) 49 (100) 48 (96.0) 49 (94.2) 48 (96.0) 49 (98.0) 292 (97.0)
BMI (kg/m2), mean (SD) 26.97 (5.30) 26.12 (4.83) 25.43 (3.93) 27.31 (4.61) 27.10 (5.24) 26.88 (4.21) 26.64 (4.72)
Region, n (%)
Western countries* 39 (78.0) 39 (79.6) 40 (80.0) 41 (78.8) 39 (78.0) 40 (80.0) 238 (79.1)
RoW† 11 (22.0) 10 (20.4) 10 (20.0) 11 (21.2) 11 (22.0) 10 (20.0) 63 (20.9)
HLA-B27 positive, % 74.0 78.7 76.0 78.8 78.0 81.6 77.9
Baseline characteristics
Duration of AS (years
since diagnosis),
mean (SD)
9.45 (8.31) 8.50 (10.30) 8.55 (10.65) 7.13 (7.96) 7.13 (7.08) 5.55 (5.31) 7.71 (8.48)
Screening hs-CRP level, n (%)
≤1.5 mg/dL 28 (56.0%) 27 (55.1%) 27 (54.0%) 29 (55.8%) 28 (56.0%) 27 (54.0%) 166 (55.1%)
Number of prior DMARDs, n (%)
None 41 (82.0) 41 (83.7) 39 (78.0) 39 (75.0) 40 (80.0) 44 (88.0) 244 (81.1%)
1 8 (16.0) 8 (16.3) 11 (22.0) 13 (25.0) 10 (20.0) 6 (12.0) 56 (18.6%)
2 1 (2.0) 0 0 0 0 0 1 (0.3%)
History of smoking n (%) 27 (54.0) 30 (61.2) 21 (42.0) 27 (51.9) 28 (56.0) 31 (62.0) 164 (54.5%)
Alcohol use, n (%) 33 (66.0) 36 (73.5) 33 (66.0) 33 (63.5) 32 (64.0) 36 (72.0) 203 (67.4%)
ASAS individual core components (0–10 scale)
Back pain, mean (SD) 6.62 (2.14) 6.73 (1.88) 6.60 (1.57) 6.91 (1.70) 6.90 (1.66) 6.52 (1.63) 6.72 (1.76)
Physical function, mean (SD) 4.44 (1.63) 4.24 (1.58) 4.05 (1.45) 4.25 (1.66) 3.99 (1.68) 3.95 (1.62) 4.15 (1.60)
Patient global assessment,
mean (SD)
6.88 (1.97) 6.82 (1.88) 6.44 (1.75) 6.94 (1.70) 6.78 (1.67) 6.48 (1.62) 6.72 (1.76)
Inflammation, mean (SD) 6.91 (2.12) 6.21 (1.73) 6.55 (1.56) 6.49 (1.96) 7.05 (1.82) 6.26 (1.88) 6.58 (1.87)
MRI (ASspiMRI) total score
Number 49 48 50 52 49 50 298
Mean (SD) 8.8 (8.8) 6.8 (7.6) 7.8 (11.1) 9.1 (11.0) 9.2 (10.2) 9.7 (9.7) 8.6 (9.8)
‘Inflammation’ represents mean of intensity and duration of morning stiffness from BASDAI. ‘Alcohol use’ is defined as any consumption of an alcoholic beverage that occurs at least
monthly or more frequently (this is “daily”, “weekly”, or “monthly”)
*Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Spain, The Netherlands, USA.
†Lithuania, Poland, Turkey.
AS, ankylosing spondylitis; ASAS, Axial SpondyloArthritis international Society; ASspiMRI, Ankylosing Spondylitis spine MRI-active score; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; BMI, Body Mass Index; DMARD, disease modifying anti-rheumatic drug; hs-CRP, high-sensitivity C-reactive protein; RoW, rest of world.
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An analysis of covariance model, including terms for baseline,
treatment, screening hs-CRP level and region, was used to assess
treatment differences in change from baseline for continuous
efﬁcacy variables. Descriptive statistics including number of sub-
jects, mean, median, minimum and maximum were provided.
Additionally, difference in least-square means, the corresponding
95% CIs and the p values were provided for comparisons of
each sarilumab dose versus placebo.
Active inﬂammation in the spine visible on MRI short tau
inversion recovery sequence was analysed by applying the MRI
score for ASspiMRI-a, as has been described before.24
Safety analysis
Safety summaries were descriptive and no hypothesis testing was
conducted. Summary of treatment-emergent adverse events
(TEAEs) was based on Medical Dictionary for Regulatory
Activities coding of verbatim terms reported by investigators.
TEAEs were deﬁned as any AEs that newly developed or wor-
sened, or became serious on or after the day of ﬁrst dose intake
of study drug, up to the day of end of study. The incidences of
abnormal laboratory values, vital signs and ECG parameters
were recorded.
RESULTS
Patients
Overall, 301 patients comprised the intention-to-treat (ITT) popu-
lation and were randomised to treatment between 4 February
2010 and 21 June 2011 (ﬁgure 1). One patient (150 mg qw
group) withdrew informed consent prior to the ﬁrst scheduled
treatment and is included in ITT efﬁcacy analyses and excluded
from safety analyses. Thirty-nine patients discontinued study treat-
ment before week 12. AEs or lack of efﬁcacy were the most
common reasons for treatment discontinuation; other reasons
included withdrawal of consent (three patients), randomisation by
mistake (two patients) and lost-to-follow-up (one patient). There
were no deaths.
Demographics, baseline and treatment characteristics
Baseline demographic and disease characteristics were similar
across all treatment groups (table 1). The majority of patients
had the HLA–B27 antigen.
Primary efﬁcacy
At week 12, there was no statistically signiﬁcant difference in
ASAS20 response between placebo (24.0%) and any of the sarilu-
mab doses (24.5, 30.0, 19.2, 30.0 and 38.0%, respectively for
100 mg q2w, 150 mg q2w, 100 mg qw, 200 mg q2w and
150 mg qw) (ﬁgure 2A). The response was greatest in the highest
dose regimen tested, 150 mg qw (38.0%), but was not statistically
signiﬁcant versus placebo (nominal and adjusted p values >0.05 vs
placebo).
A treatment interaction was observed based on screening
hs-CRP value with evidence of a signiﬁcant ASAS20 treatment
response among patients with hs-CRP >1.5 mg/dL (p=0.0493).
However, this effect appears to be limited to one dose group
only (150 mg qw) (ﬁgure 2B). Other subgroup interaction analyses
for ASAS20 were not signiﬁcantly different, including gender
(men vs women, p=0.8571), race (Caucasian vs all other races,
p=0.9998), past history of anti-TNFs (yes vs no, p=0.8373),
region (Western countries vs non-Western countries) (p=0.9082),
number of prior DMARDs (none, 1, 2, ≥3, p=0.2342) and
smoking history (yes vs no, p=0.7207).
Secondary efﬁcacy
Secondary efﬁcacy end points at week 12 showed that the rates of
ASAS40 response, ASAS partial remission, and ASAS5/6 response
were generally not signiﬁcantly different from placebo. Only the
ASAS5/6 response rate in the 150 mg qw group (n=16, 32.0%)
showed a signiﬁcant difference versus placebo (n=3, 6.0%:
p=0.001; OR 6.4 (CI 1.8 to 22.8)) (table 2). In regard to the four
individual ASAS core components (back pain, physical function,
patient global assessment and inﬂammation) at week 12, only back
pain in the 150 mg qw dose group showed a statistically signiﬁ-
cantly higher treatment effect (change from baseline) compared to
placebo: mean (SD) change −1.6 (2.1) vs −0.8 (1.8), p=0.0344. A
signiﬁcantly higher treatment effect was seen at the higher sarilu-
mab doses compared to placebo for ASDAS score mean (SD)
change −0.4 (0.7), −0.8 (1.2), −1.1 (0.8), −1.2 (0.9), and −1.6
Figure 2 Incidence of ASAS20 response – ITT population. Percentage
response calculated using the number of ITT patients in the
corresponding treatment group within each subgroup as denominator.
At week 12, p>0.05 (nominal and adjusted) for all sarilumab-treated
groups vs placebo. CRP, high sensitivity C-reactive protein; ITT,
intent-to-treat.
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(0.9) respectively for placebo, 150 mg q2w, 100 mg qw,
200 mg q2w and 150 mg qw; p=0.0112 for 150 mg q2w and
p<0.0001 for each of the other three doses versus placebo.
Sarilumab at doses greater than 150 mg q2w signiﬁcantly
reduced hs-CRP values compared to placebo; mean (SD) mg/dL
change that is, placebo −3.7 (19.1), 100 mg q2w −1.2 (17.9,
not signiﬁcant (ns)), 150 mg q2w −5.8 (27.6, ns), 100 mg qw
−13.5 (20.3, p=0.0007), 200 mg q2w −11.5 (17.5, p<0.0001),
and 150 mg qw −14.3 (15.3, p<0.0001).
Changes from baseline for BASDAI and BASMI scores and
chest expansion, were not statistically different from placebo at all
sarilumab doses tested. Only small changes were observed for the
MRI spine score in all groups (table 2), which did not differ signiﬁ-
cantly between the placebo-treated and sarilumab-treated groups.
Correlation coefﬁcients between change from baseline in MRI
score and change from baseline in hs-CRP value at week 12 were
0.04 for the placebo group and ranged from −0.03 to 0.19 for the
sarilumab groups (p=ns for all groups).
Safety
Mean treatment duration (76.2–81.4 days), treatment exposure
(10.5–11.0 patient-years) and overall treatment compliance
(94–100%) were comparable across all treatment groups. The
proportion of patients who experienced at least one TEAE was
∼twofold higher in the sarilumab groups (64%–78%, and with
no clear dose response relationship), compared with 36% in the
placebo group (see online supplemental table 1). Infections and
infestations, particularly upper respiratory tract infections, were
the most common TEAE reported by all groups. Twelve cases of
accidental overdose (deﬁned as administration of at least twice
the treatment dose during fewer than 6 days) were reported;
all cases were asymptomatic.
Overall, 20 patients on sarilumab experienced a TEAE that
led to treatment discontinuation, the most frequent being neu-
tropenia (n=6), gastrointestinal disorders (n=5) and increased
alanine aminotransferase (ALT) (n=4). All events leading to dis-
continuation resolved following treatment cessation with the
exception of Crohn’s disease (n=1; diagnosis reported in a
patient with a previous history of colitis and anterior uveitis).
Serious TEAEs were infrequent (seven patients). All reported
events occurred in the sarilumab groups; of these, ﬁve events
(one per patient) resulted in treatment discontinuation (neutro-
penia, ALT increase, helicobacter gastritis, false positive tubercu-
losis test and epileptic seizure) (further details are provided in
the online supplemental table 2). No severe or serious infections
were associated with grade 3 (≥500–1000/mm3) or grade
4 (<500/mm3) neutropenia, and no deaths were reported.
Sarilumab was associated with neutropenia and elevations in
ALT (>3×upper limit of normal), total cholesterol and low-
density lipoprotein. Generally, changes in other laboratory tests,
vital signs and ECG parameters were not considered clinically
signiﬁcant.
DISCUSSION
The ALIGN study showed that SC-administered sarilumab was
generally well tolerated but did not demonstrate a statistically or
clinically signiﬁcant effect compared to placebo in patients with
active AS who had an inadequate response to, or were intolerant
of, NSAIDs. A statistically signiﬁcant reduction in hs-CRP fol-
lowing SC sarilumab treatment demonstrated that a biological
effect of IL-6 blockade was achieved. However, lack of asso-
ciated clinical or imaging improvement that is, similar reduc-
tions in functional and clinical parameters as measured by MRI,
BASDAI, BASMI and BASFI scores in placebo-treated and
sarilumab-treated patients, further suggests that IL-6 may not
play a major role in the inﬂammatory process underlying AS.
The signiﬁcant reduction observed in the ASDAS score with sar-
ilumab likely reﬂects inclusion of hs-CRP in this composite
measure, suggesting that ASDAS may not be a robust outcome
parameter when changes in CRP values could be dissociated
Table 2 Secondary efficacy endpoints at week 12—ITT population
Sarilumab
Placebo
(n=50)
100 mg q2w
(n=49)
150 mg q2w
(n=50)
100 mg qw
(n=52)
200 mg q2w
(n=50)
150 mg qw
(n=50)
Incidence of key secondary efficacy endpoint—responders
ASAS40, n (%) 4 (8.0) 7 (14.3) 8 (16.0) 3 (5.8) 9 (18.0) 10 (20.0)
ASAS partial remission, n (%) 1 (2.0) 4 (8.2) 1 (2.0) 1 (1.9) 1 (2.0) 4 (8.0)
ASAS5/6 response, n (%) 3 (6.0) 6 (12.2) 5 (10.0) 7 (13.5) 7 (14.0) 16 (32.0)*
Change from baseline in key secondary efficacy components
ASAS individual core component change, mean (SD) (0–10 scale)
Back pain −0.8 (1.8) −1.3 (2.2) −1.2 (2.4) −0.5 (1.8) −0.9 (2.2) −1.6 (2.1)
Physical function −0.6 (1.2) −0.5 (1.7) −0.4 (2.0) −0.1 (1.4) −0.6 (1.9) −1.1 (1.9)
Patient global assessment −1.0 (1.9) −1.1 (2.3) −0.8 (2.3) −0.4 (2.2) −0.9 (2.2) −1.6 (2.0)
Inflammation −1.4 (1.8) −0.8 (2.0) −1.1 (2.0) −0.7 (2.1) −1.0 (1.9) −1.8 (2.3)
ASspiMRI total score change, mean (SD) −0.5 (2.2) −0.5 (1.8) −0.1 (3.4) 0.1 (2.4) −0.3 (3.3) 0.3 (3.3)
ASDAS score change, mean (SD) −0.4 (0.7) −0.5 (0.9) −0.8 (1.2) −1.1 (0.8) −1.2 (0.9) −1.6 (0.9)
BASDAI score change, mean (SD) −0.9 (1.7) −0.8 (1.9) −1.1 (2.0) −0.4 (1.4) −0.9 (1.8) −1.2 (1.8)
BASMI score change, mean (SD) −0.2 (0.8) −0.2 (0.9) −0.2 (0.8) −0.4 (0.9) −0.1 (0.8) −0.2 (0.7)
hs-CRP (mg/dl) change, mean (SD) −3.7 (19.1) −1.2 (17.9) −5.8 (27.6) −13.5 (20.3)** −11.5 (17.5)*** −14.3 (15.3)***
Chest expansion (cm) change, mean (SD) 0.2 (1.0) 0.2 (1.2) 0.0 (1.2) −0.1 (0.9) 0.1 (1.3) 0.3 (1.3)
n = number of patients with assessment at baseline and week 12. Percentages calculated using the number of ITT patients in the corresponding treatment group as denominator.
*p<0.01; **p<0.001; ***p<0.001, each versus placebo.
‘Inflammation’ represents mean of intensity and duration of morning stiffness from BASDAI.
ASAS, Axial SpondyloArthritis International Society response criteria; ASDAS, AS Disease Activity Score; ASspiMRI, AS spine MRI-active score; BASDAI, Bath AS Disease Activity Index;
BASMI, Bath AS Metrology Index; hs-CRP, high-sensitivity C-reactive protein; ITT, intent-to-treat.
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from changes in disease activity, as with anti-IL-6 therapies.
Variability in the observed efﬁcacy of sarilumab among individ-
ual treatment groups in the ALIGN study most likely reﬂects the
inclusion of only 49–52 subjects in each individual treatment
group, since no sarilumab dose group yielded a statistically sig-
niﬁcantly greater proportion of ASAS20 responders when com-
pared to the placebo group (ﬁgure 2A, p>0.05 for all groups).
Variability of ASAS20 response at week 12 by hs-CRP stratiﬁca-
tion among sarilumab groups (ﬁgure 2B) potentially supports
this assertion.
There was no relationship between changes in hs-CRP and
changes in the MRI scores, suggesting that the drug did not
have an effect on AS disease-speciﬁc inﬂammation.
Although case reports of treatment with TCZ have suggested
beneﬁt of IL-6Rα blockade in AS,16–19 a recent 12-week phase
II multicentre, randomised, double-blind, placebo-controlled
study of TCZ in AS patients did not conﬁrm this. That study
used the same primary efﬁcacy end point as the ALIGN study to
compare intravenous TCZ 8 mg/kg versus placebo in 102 AS
patients (TCZ, n=51; placebo, n=51). Similar to sarilumab,
TCZ also failed to reach its primary efﬁcacy end point despite
reducing hs-CRP and ASDAS scores.20 These results caution
that positive case reports or evidence for a certain pharmaco-
logical intervention based on preclinical data, may not always
predict the clinical efﬁcacy of a targeted drug in complex dis-
eases of unknown aetiology such as AS. Anti-IL-6Rα therapies
have shown efﬁcacy in RA.15 25 26 Sarilumab was studied in the
treatment of RA in the phase II/III MOBILITY study
(NCT01061736) using the same ﬁve doses as in the current
trial. Part A of this study demonstrated efﬁcacy of sarilumab in
addition to MTX in patients with active, moderate-to-severe RA
who had inadequate response to MTX.27 Several other drugs
with proven efﬁcacy in RA, including sulfasalazine, leﬂunomide,
MTX, anakinra, rituximab and abatacept, have been investigated
for the treatment of AS and, thus far, none has shown any clear
therapeutic efﬁcacy.28 TNF-blockers appear to be effective
across a number of inﬂammatory rheumatic diseases, including
RA and AS, whereas, the efﬁcacy of other targeted therapies
may be limited to fewer speciﬁc indications. Encouraging data
from a small study in AS patients evaluating IL-17 blockade,
which has shown clinical efﬁcacy in the treatment of psoria-
sis,29 30 will require further conﬁrmation.31
In the current study in AS patients, sarilumab showed a safety
proﬁle similar to reports with other IL-6 inhibitors. Infections
and laboratory abnormalities, including neutropenia, elevated
transaminases and hyperlipidaemia, were the most commonly
observed safety ﬁndings.
CONCLUSION
The ALIGN study did not demonstrate efﬁcacy of sarilumab
versus placebo for the treatment of active AS, irrespective of a
marked reduction in hs-CRP. Thus, the IL-6 pathway does not
appear to play an essential role in AS clinical disease activity and
may not be an effective drug target for the disease.
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